Immunocore Limited presented data from the IMCgp100-102 trial at the American Society of Clinical Oncology meeting that showed a durable response and strong overall survival rate in patients with ...

T-cell redirection therapy using chimeric antigen receptor (CAR) T cells and/or bispecific antibody (BsAb) has been established and become a promising treatment strategy for relapsed/refractory B-cell ...

Mount Sinai researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line treatment with bispecific antibodies fails ...

Researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line treatment with bispecific antibodies fails. Bispecific ...

"Results from the MonumenTAL-1 study continue to show deeper response levels and a longer duration of response in patients treated with either of the approved dose options of talquetamab, while the ...

Washington: US-based Maverick Therapeutics and Japan-based Takeda Pharmaceutical on Wednesday announced that they have entered into a collaboration to develop Maverick’s T-cell engagement platform ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Reduced-intensity dosing of talquetamab may improve tolerability without compromising efficacy among ...

New York, NY (September 1, 2022) — Mount Sinai researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line ...

Washington: Researchers have published results that show encouraging therapeutic options for patients with blood cancer and multiple myeloma after first-line treatment with bispecific antibodies fails ...